Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Black Diamond Therapeutics Inc (BDTX)

Black Diamond Therapeutics Inc (BDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 99,185
  • Shares Outstanding, K 56,677
  • Annual Sales, $ 0 K
  • Annual Income, $ -69,680 K
  • EBIT $ -79 M
  • EBITDA $ -78 M
  • 60-Month Beta 2.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.11

Options Overview Details

View History
  • Implied Volatility 149.08% ( -40.70%)
  • Historical Volatility 87.22%
  • IV Percentile 58%
  • IV Rank 18.39%
  • IV High 492.91% on 04/23/25
  • IV Low 71.60% on 12/12/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 708
  • Volume Avg (30-Day) 136
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 5,785
  • Open Int (30-Day) 5,389

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.02
  • Number of Estimates 4
  • High Estimate 0.92
  • Low Estimate -0.32
  • Prior Year -0.35
  • Growth Rate Est. (year over year) +105.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3100 +47.33%
on 04/17/25
1.9800 -2.53%
on 05/13/25
+0.5400 (+38.85%)
since 04/11/25
3-Month
1.2000 +60.83%
on 04/09/25
2.7800 -30.58%
on 03/19/25
-0.4100 (-17.52%)
since 02/13/25
52-Week
1.2000 +60.83%
on 04/09/25
6.7500 -71.41%
on 08/22/24
-4.0100 (-67.51%)
since 05/13/24

Most Recent Stories

More News
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

BDTX : 1.9300 (+10.29%)
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

BDTX : 1.9300 (+10.29%)
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High

As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.

BDTX : 1.9300 (+10.29%)
VTI : 289.22 (+0.68%)
IWM : 208.63 (+0.37%)
Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

BDTX : 1.9300 (+10.29%)
Black Diamond: Q4 Earnings Snapshot

Black Diamond: Q4 Earnings Snapshot

BDTX : 1.9300 (+10.29%)
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

BDTX : 1.9300 (+10.29%)
Black Diamond: Q3 Earnings Snapshot

Black Diamond: Q3 Earnings Snapshot

BDTX : 1.9300 (+10.29%)
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

BDTX : 1.9300 (+10.29%)
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

BDTX : 1.9300 (+10.29%)
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

BDTX : 1.9300 (+10.29%)

Business Summary

Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor...

See More

Key Turning Points

3rd Resistance Point 2.2600
2nd Resistance Point 2.1200
1st Resistance Point 2.0250
Last Price 1.9300
1st Support Level 1.7900
2nd Support Level 1.6500
3rd Support Level 1.5550

See More

52-Week High 6.7500
Fibonacci 61.8% 4.6299
Fibonacci 50% 3.9750
Fibonacci 38.2% 3.3201
Last Price 1.9300
52-Week Low 1.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar